US equities
|
SPCX
$175.24
▲+2.43%
NVDA
$242.54
▲+1.52%
MU
$1,065.45
▲+0.14%
MRVL
$291.52
▲+7.47%
AMD
$650.01
▲+2.89%
SNDK
$1,668.97
▼-2.06%
AVGO
$377.38
▲+4.10%
TSLA
$380.86
▲+0.56%
SPCX
$175.24
▲+2.43%
NVDA
$242.54
▲+1.52%
MU
$1,065.45
▲+0.14%
MRVL
$291.52
▲+7.47%
AMD
$650.01
▲+2.89%
SNDK
$1,668.97
▼-2.06%
AVGO
$377.38
▲+4.10%
TSLA
$380.86
▲+0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Regeneron Pharmaceuticals
(NQ:
REGN
)
729.74
+3.27 (+0.45%)
Delayed Quote
Updated: 10:43 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Today 7:00 EDT
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Regeneron (REGN) Stock Is Trading Lower Today
October 01, 2026
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all...
Via
StockStory
Which S&P500 stocks are moving on Thursday?
↗
October 01, 2026
Via
Chartmill
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
October 01, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
October 01, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount
↗
September 09, 2026
Via
Chartmill
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
↗
October 01, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,...
Via
MarketBeat
Topics
ETFs
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
October 01, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
September 30, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...
Via
StockStory
Topics
Artificial Intelligence
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
↗
September 28, 2026
The healthcare company will release its third-quarter results next month.
Via
The Motley Fool
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
September 28, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Via
StockStory
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
September 24, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
↗
September 23, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development...
Via
MarketBeat
Topics
ETFs
Is Regeneron Stock a Bargain Below $800?
↗
September 22, 2026
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.
Via
The Motley Fool
Topics
Intellectual Property
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
September 22, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via
StockStory
Topics
Stocks
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 15, 2026
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Via
The Motley Fool
Topics
Regulatory Compliance
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
↗
September 14, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global...
Via
MarketBeat
Topics
Intellectual Property
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
September 14, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 14, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 14, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
↗
September 12, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo...
Via
MarketBeat
Topics
ETFs
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
September 11, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
September 10, 2026
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
September 10, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 10, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
September 08, 2026
From
Pomerantz LLP
Via
GlobeNewswire
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Deadline
September 08, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
September 08, 2026
Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that p...
Via
StockStory
Topics
Stocks
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 07, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
↗
September 04, 2026
They could both outperform the market over the medium term, but one appears to have a clear edge.
Via
The Motley Fool
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
